CGEN

Rating neutralAI Memo

Compugen

As of 2026-08-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

MAIA-ovarian interim PFS analysis • 2026-11-04

Base target: $2 / p=50% prob

Biggest risk

CGEN remains a low-coverage, clinical-stage biotech with no established product revenue base. The central value driver is a binary clinical milestone, and Q2 R&D expense remained higher year over year. Post-print analyst revisions or target changes were not verified in the bounded search.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The Q2 revenue and EPS results appear better than the packet's pre-print consensus, while the company reiterated its MAIA-ovarian timing, partner-program progress, and runway into 2029. A successful interim PFS result could support substantial upside.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-06

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 2026 beat improved near-term tone
Partnered pipeline progress and extended runway
The Q2 revenue and EPS results appear better than the packet's pre-print consensus, while the company reiterated its MAIA-ovarian timing, partner-program progress, and runway into 2029.

BearKey bullets

MAIA-ovarian interim PFS data could disappoint, be delayed, or fail to establish a registration path.
Post-earnings analyst revisions and a clean event-specific market-reaction attribution were not available in the bounded evidence.
R&D spending remains material relative to revenue; the reported runway depends on current operating plans and excludes additional cash inflows.

WatchKey bullets

MAIA-ovarian interim PFS analysis

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=50%)

Target spread vs base: +92% / -42%

Scenario probabilities

Bull Target: $5 (p=20%)Base Target: $2 (p=50%)Bear Target: $1 (p=30%)

Commentary

The Q2 print was operationally mixed-to-positive: revenue and EPS were better than the packet's pre-print consensus, while the company maintained its clinical timetable and runway. The Aug. 5 RankAlpha anchor was $2.28, but a clean post-release price-reaction series and verified post-print analyst revisions were unavailable. This remains a cautious, low-coverage biotech monitoring view. [Compugen Q2 2026 release](https://www.prnewswire.com/news-releases/compugen-reports-second-quarter-2026-results-302841059.html) [#PR-2026-08-03]

As of 2026-08-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 2026 beat improved near-term tone
Partnered pipeline progress and extended runway

Scenarios

Bull Target (Scenario probability)

$5 / p=20% prob

Base Target (Scenario probability)

$2 / p=50% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-11-04
MAIA-ovarian interim PFS analysis
The company said its randomized MAIA-ovarian trial remains on track for median progression-free-survival data by Q1 2027. This is the clearest potential valuation-reset event, but remains binary and clinically uncertain. [Compugen Q2 2026 release](https://www.prnewswire.com/news-releases/compugen-reports-second-quarter-2026-results-302841059.html) [#PR-2026-08-03]
Prob 50.00% • Move 35.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Q2 2026 beat improved near-term tone
2026-08-03
Compugen reported Q2 revenue of approximately $2.6 million and a net loss of $0.07 per share, versus the packet's pre-print consensus of $1.61 million and -$0.08 per share. The release also showed a modest year-over-year reduction in net loss. [Compugen Q2 2026 release](https://www.prnewswire.com/news-releases/compugen-reports-second-quarter-2026-results-302841059.html) [SEC Q2 financial statements](https://www.sec.gov/Archives/edgar/data/1119774/000117891326003754/exhibit_99-2.htm) [#PR-2026-08-03] [#SEC-6K-2026-08-03]
Prob 80% • Move 5% • Priced-in 70%

Long-term Catalysts

Months to a year

Partnered pipeline progress and extended runway
2027-08-06
AstraZeneca is advancing rilvegostomig across 12 Phase 3 trials, while the Gilead-partnered GS-0321 Phase 1 trial is progressing as planned. Compugen reported approximately $125.3 million in cash and investments, no debt, and expected funding into 2029. [Compugen Q2 2026 release](https://www.prnewswire.com/news-releases/compugen-reports-second-quarter-2026-results-302841059.html) [#PR-2026-08-03]
Prob 55% • Move 15% • Priced-in 50%

Risks

MAIA-ovarian interim PFS data could disappoint, be delayed, or fail to establish a registration path.
Post-earnings analyst revisions and a clean event-specific market-reaction attribution were not available in the bounded evidence.
R&D spending remains material relative to revenue; the reported runway depends on current operating plans and excludes additional cash inflows.
The company remains dependent on clinical execution and partnered-program milestones rather than recurring commercial revenue.

Peers

Symbol	Summary
ANTX	Same-sector, similar-market-cap candidate; useful only for framing small-cap clinical-biotech event risk, with direct operating comparability unverified.
GLSI	Same-sector, similar-market-cap candidate; not a confirmed direct therapeutic or indication peer.
WHWK	Same-sector, similar-market-cap candidate; useful as a broad development-stage biotech risk reference rather than a valuation anchor.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-06

Loading AI feed…

Symbol

Summary

ANTX

Same-sector, similar-market-cap candidate; useful only for framing small-cap clinical-biotech event risk, with direct operating comparability unverified.

GLSI

Same-sector, similar-market-cap candidate; not a confirmed direct therapeutic or indication peer.

WHWK

Same-sector, similar-market-cap candidate; useful as a broad development-stage biotech risk reference rather than a valuation anchor.